CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for AstraZeneca plc (ADR) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

AstraZeneca plc (ADR)
1 Francis Crick Avenue
Phone: +44 2073045000p:+44 2073045000 CAMBRIDGE, CB2 0AA  United Kingdom Ticker: AZNAZN

Business Summary
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-Yes-YesYes--

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Non-Executive Chairman of the Board LeifJohansson 68 6/1/2012 4/26/2012
Chief Executive Officer, Executive Director PascalSoriot 59 10/1/2012 10/1/2012
Chief Financial Officer, Executive Director MarcDunoyer 11/1/2013 1/1/2013
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Acerta Pharma B.V.
AstraZeneca AB
AstraZeneca Biotech AB
14 additional Business Names available in full report.

General Information
Number of Employees: 64,400 (As of 12/31/2018)
Outstanding Shares: 1,311,783,132 (As of 9/30/2019)
Shareholders: 83,588
Stock Exchange: NYSE
Fax Number: +44 2076048151
Email Address: investor-relations@astrazeneca.com


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 06, 2019